Jefferies Global Industrial Conference 2024
Logotype for Donaldson Company Inc

Donaldson Company (DCI) Jefferies Global Industrial Conference 2024 summary

Event summary combining transcript, slides, and related documents.

Logotype for Donaldson Company Inc

Jefferies Global Industrial Conference 2024 summary

22 Jan, 2026

Strategic direction and technology leadership

  • Focused on technology leadership with over 2,700 active patents and a proprietary approach across all business segments.

  • Operates in three segments: Mobile Solutions, Industrial Solutions, and Life Sciences, with a balanced mix of original equipment and replacement parts.

  • Strategic growth is targeted and balanced, with recent entry and expansion in the Life Sciences market.

  • Maintains a global presence, manufacturing 75% of products within the region they are sold, supporting strong customer relationships.

  • Diversified portfolio enables resilience against market headwinds and supports long-term profitability.

Financial performance and outlook

  • Achieved record revenues and earnings in recent years, with mid-single-digit sales growth expected to continue.

  • Operating margin expanded from 13.5% to 15.4% over three years, with a target to reach high 15% in the current fiscal year.

  • Fiscal 2026 targets include 3–7% CAGR and an increased operating margin of 16.2%.

  • Strong balance sheet with net debt to EBITDA at 0.5, supporting ongoing acquisitions and cash management.

  • Free cash flow conversion is near 100%, with capital allocated primarily to organic/inorganic growth and dividends.

Innovation, digitalization, and market expansion

  • Digitization of industrial solutions, such as connected dust collectors, drives higher aftermarket sales and margin benefits.

  • Expansion of digital solutions to India, China, and Thailand, with simplified installation and broader compatibility.

  • Life Sciences segment targets cell and gene therapy markets, leveraging both organic growth and niche acquisitions.

  • Recent acquisitions include Purilogics (membrane-based chromatography) and Medica (hollow fiber membranes), with new products expected in coming quarters.

  • Proprietary solvent reclamation technology in Life Sciences enables new business opportunities and significant cost savings for customers.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more